Breast Surgery
Post-trial follow-up | Radiotherapy vs. surgery of the axilla after a positive sentinel node in breast cancer.
14 Dec, 2022 | 14:42h | UTCRadiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: ART Preferred Over ALND in Sentinel Node-Positive Early Breast Cancer – Cancer Therapy Advisor
Post-trial follow-up | Long-term outcomes of adjuvant denosumab in breast cancer.
22 Nov, 2022 | 13:14h | UTCLong-Term Outcomes of Adjuvant Denosumab in Breast Cancer – NEJM Evidence
Original Study: Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial – The Lancet (link to abstract – $ for full-text)
Cohort Study | Use of breast cancer risk factors may identify risk-adapted starting age of screening.
18 Nov, 2022 | 13:16h | UTCInvited Commentary: Risk-Based Approaches to Breast Cancer Screening in China – JAMA Network Open
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1590766235989708801
Phase 2 RCT | Non-hormonal drug reduces vasomotor symptoms in women taking oral adjuvant endocrine therapy after breast cancer.
15 Nov, 2022 | 12:58h | UTC
RCT | Comparison of acupuncture vs. sham acupuncture in the treatment of aromatase inhibitor–related joint pain.
15 Nov, 2022 | 12:47h | UTC
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1591113526222913538
RCT | Preoperative ultrasound-guided percutaneous cryoneurolysis for the treatment of pain after mastectomy.
10 Nov, 2022 | 13:41h | UTCInfographic: Tip of the Iceberg: The History of Cryoneurolysis – Anesthesiology
Single-arm P2 study | Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy.
2 Nov, 2022 | 14:23h | UTCEliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Elimination of Surgery Explored for Selected Breast Cancer Patients – HealthDay
Commentary on Twitter
Online first: #Eliminating breast #surgery for invasive #breastcancer in exceptional #responders to #neoadjuvant systemic #therapy: a multicentre, single-arm, phase 2 trial https://t.co/lxZa62zFZT pic.twitter.com/TS1dKqFhF1
— The Lancet Oncology (@TheLancetOncol) October 26, 2022
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
31 Oct, 2022 | 13:50h | UTC
Nonsurgical options for risk reduction of contralateral breast cancer in BRCA mutation carriers with early breast cancer.
31 Oct, 2022 | 13:41h | UTCNonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer – Journal of Clinical Oncology (free for a limited period)
Guideline | Reporting of surgically removed lymph nodes for breast tumors.
25 Oct, 2022 | 13:20h | UTC
Cohort Study | Systemic or vaginal hormone therapy after early breast cancer.
24 Oct, 2022 | 14:00h | UTCNews Release: Hormone replacement therapy doesn’t lead to breast cancer reoccurrence – Oxford University Press
Commentaries:
Hormone Replacement Therapy Won’t Raise Recurrence Rate for Breast Cancer Survivors – HealthDay
Recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.
14 Oct, 2022 | 14:12h | UTC
Cohort Study | Elevated C-reactive protein and subsequent patient-reported cognitive problems in older breast cancer survivors.
14 Oct, 2022 | 14:03h | UTC
Cohort Study | Association of long-term oncologic prognosis with minimal access breast surgery vs. conventional breast surgery.
13 Oct, 2022 | 13:38h | UTC
Commentary on Twitter
A single-center retrospective cohort study found that the long-term outcomes of minimal-access breast surgery are not significantly different from those of conventional #BreastSurgery in patients with stage 0-III #BreastCancer. https://t.co/SMQWCNSa4X
— JAMA Surgery (@JAMASurgery) October 6, 2022
RCT | Antibiotic prophylaxis vs. no prophylaxis in breast cancer surgery.
3 Oct, 2022 | 13:47h | UTCAntibiotic prophylaxis in breast cancer surgery (PAUS trial): randomised clinical double-blind parallel-group multicentre superiority trial – British Journal of Surgery (link to abstract – $ for full-text)
20-year follow-up of a RCT | Adjuvant Goserelin and Tamoxifen in premenopausal patients with breast cancer.
26 Sep, 2022 | 12:00h | UTCNews Release: Hormonal breast cancer treatment reduces long-term risk of recurrence – Karolinska Institutet
Commentary on Twitter
20-yr FU of the STOCKHOLM trial in pts with premenopausal #breastcancer reveals that those with genomic low-risk benefited most from tamoxifen & those with genomic high-risk from goserelin, with no benefit from combined goserelin-tamoxifen in either group: https://t.co/UDKo5huaFA
— NatureRevClinOncol (@NatRevClinOncol) August 4, 2022
RCT | Outpatient vs. inpatient preinduction cervical ripening using a synthetic osmotic dilator.
26 Sep, 2022 | 11:58h | UTC
M-A | Margin status and survival outcomes after breast cancer conservation surgery.
23 Sep, 2022 | 13:09h | UTCCommentary from the authors: Width of excision margins after breast conserving surgery for invasive breast cancer and distant recurrence and survival – The BMJ
News Release: Experts call for adequate tumour free margins in breast cancer surgery – BMJ Newsroom
RCT | Multiple doses of prophylactic intravenous antibiotics are no better than a single dose in implant-based breast reconstruction.
19 Sep, 2022 | 12:48h | UTC
Commentary on Twitter
Multiple-dose antibiotic prophylaxis was not superior to a single-dose regimen in preventing surgical site infection and implant removal after implant-based breast reconstruction in this RCT. https://t.co/p7GbNRMPfW #OAResarch
— JAMA Network Open (@JAMANetworkOpen) September 16, 2022
Cohort Study | Fertility preservation procedures appear to be safe at the time of breast cancer diagnosis.
7 Sep, 2022 | 12:31h | UTCNews Release: Fertility preservation measures do not appear to increase the risk of breast cancer recurrence – Karolinska Institutet
Cohort Study | 5-year follow-up results suggest it is safe to de-escalate radiotherapy after primary chemotherapy in cT1–2N1 breast cancer.
31 Aug, 2022 | 11:45h | UTCDe-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
At 5-year follow up in RAPCHEM, BOOG 2010–03 study of locoregional RT de-escalation in cT1-2N1 breast cancer, locoregional recurrence rates were 2.3%, 1.0% and 1.4% in low, intermediate and high risk groups, and therefore this approach was considered safe: https://t.co/4NkUwr4kxV
— NatureRevClinOncol (@NatRevClinOncol) August 15, 2022
Spindle cell lesions of the breast: a diagnostic algorithm.
23 Aug, 2022 | 12:51h | UTC
RCT | Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast.
9 Aug, 2022 | 12:46h | UTCRadiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
Cohort Study | Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
9 Aug, 2022 | 12:20h | UTC
Commentary on Twitter
Out on NPJ Breast a new report on #ERlowtumors. No difference in characteristics, pCR rates, RFS os OS compared with #TNBC. Patients with ER-low tumors should be treated as for TNBC. Also, important confounder to remember in HER2-low prognostic analyses.https://t.co/M1GF8eyYbT pic.twitter.com/CrLyUgyhUV
— Paolo Tarantino (@PTarantinoMD) July 11, 2022
RCT | Partial breast irradiation vs. whole breast irradiation for early breast cancer.
8 Aug, 2022 | 11:36h | UTCPartial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)